1. The Use of Saxagliptin in People with Type 2 Diabetes in France: The Diapazon Epidemiological Study
- Author
-
Beverley Balkau, Celine Faure, Amir Lahouegue, Bernard Charbonnel, Alfred Penfornis, Nora Chraibi, Florence Thomas-Delecourt, and Bruno Detournay
- Subjects
medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,Type 2 diabetes ,030204 cardiovascular system & hematology ,Saxagliptin ,Hypoglycemia ,03 medical and health sciences ,chemistry.chemical_compound ,Diabetes mellitus ,0302 clinical medicine ,Hypoglycemic agents ,Observational study ,Internal medicine ,Internal Medicine ,Medicine ,Original Research ,Glycemic ,business.industry ,medicine.disease ,Discontinuation ,Metformin ,Regimen ,chemistry ,Cohort ,business ,medicine.drug - Abstract
Introduction Saxagliptin is a potent, reversible inhibitor of dipeptidyl peptidase-4 that is indicated for the treatment of type 2 diabetes. The DIAPAZON study was a multicenter observational study intended to document the effectiveness, safety and patterns of saxagliptin use in France, including the saxagliptin retention rate, over 2 years of follow-up. Methods A geographically representative sample of 304 French physicians (general practitioners and specialist endocrinologists or diabetologists) recruited 1131 adults with type 2 diabetes into an ambispective cohort; 1033 fulfilled the inclusion criteria. All had started saxagliptin during the previous 6 months or at study inclusion, and follow-up was for 24 ± 3 months after starting saxagliptin. Results The mean age of the study population when starting saxagliptin was 61 years, and the mean HbA1c level was 8.0%; 79% had an HbA1c level ≥7%. Prior to starting saxagliptin treatment, most participants (91%) were receiving treatment with oral glucose-lowering drugs alone. The most commonly prescribed regimen at starting saxagliptin (53% of participants) was a combination of saxagliptin and metformin. The overall saxagliptin retention rate at 2 years was 79%, as estimated by the Kaplan-Meier method. The most common reasons for discontinuation were inadequate glycemic control (52%) and intolerance (22%). During the course of the study, the mean HbA1c level decreased to 7.0%, and the percentage of people with HbA1c
- Published
- 2017